Jiangsu Cowin Biotech Co., Ltd. Class A
SSSE:68842618.71
CNY
-0.74
(-3.80%)
ISIN
CNE100005NM2
Return %
Stock
S&P 500
1Y
-31.44
14.20
3Y
-34.67
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Chun Xiang Wang
- Full Time Employees
- 769
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Taizhou China
- IPO Date
- Oct 25, 2022
- Website
- cwbio.com
- Similar Companies
- Business
- Jiangsu Cowin Biotech Co., Ltd. is a China-based biotechnology enterprise primarily engaged in the research, development, production, and commercialization of biological reagents, molecular diagnostic products, and clinical testing services for life science research and in vitro diagnostics (IVD). Founded in 2007 and headquartered in Taizhou, Jiangsu Province, China, the company operates under the CoWin Biosciences (CWBIO) brand and maintains an integrated value chain spanning upstream enzyme raw materials, sample pre-processing technologies, downstream molecular diagnostic assays, and automated testing instrumentation. The company's product portfolio is organized into multiple core segments: molecular biology raw material enzymes, including Taq DNA polymerases, high-fidelity polymerases, reverse transcriptases, and T4 DNA ligases; nucleic acid sample collection and preservation systems, comprising saliva, swab, stool, urine, and cell-free DNA (cfDNA) preservation solutions and sample transport tubes; nucleic acid isolation and purification kits, utilizing magnetic bead and spin-column platforms for genomic DNA, viral RNA/DNA, plasmid DNA, and formalin-fixed paraffin-embedded (FFPE) tissue extraction; molecular biology reagents, encompassing standard PCR, real-time quantitative PCR (qPCR) master mixes, RT-PCR kits, and nucleic acid electrophoresis markers; next-generation sequencing (NGS) library preparation kits and genomics reagents; and clinical molecular diagnostic kits, featuring proprietary assays such as non-invasive stool-based Helicobacter pylori nucleic acid detection kits, Helicobacter pylori antimicrobial drug-resistance gene mutation detection kits, colorectal cancer methylation detection kits, and respiratory pathogen panels. In addition to reagent consumables and automated nucleic acid extraction workstations, the company delivers technical and diagnostic services, including gene synthesis, molecular cloning, sequencing support, and third-party clinical molecular testing for hospitals, research institutes, universities, pharmaceutical companies, and commercial laboratories across domestic and international markets. In recent developments, Jiangsu Cowin Biotech has accelerated the clinical commercialization and hospital adoption of its proprietary digestive disease molecular diagnostic pipeline, notably its stool-based Helicobacter pylori identification and drug-resistance mutation assays designed to guide personalized antibiotic therapy. To expand its molecular diagnostic footprint and testing capabilities, the company acquired a 51 percent majority equity stake in Shanghai Haoweitai Biotechnology Co., Ltd. from Shanghai Genergy Bio-technology Co., Ltd. Furthermore, the company has continued to broaden its global distribution network across Europe, the Americas, and the Asia-Pacific region, implemented structured equity incentive plans to retain core research and management personnel, and expanded its automated diagnostic equipment portfolio to deliver fully integrated, high-throughput sample-to-result molecular testing solutions.